Skip to main content
SpringerLink
Log in

Linagliptin possibly enhances the efficacy of allosteric xanthine oxidase inhibitors

  • Nephrology - Letter to the Editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Data availability

Data are available on request.

References

  1. Mitsuboshi S, Yamada H, Nagai K, Okajima H (2015) Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients. J Pharm Health Care Sci 1:28. https://doi.org/10.1186/s40780-015-0028-1

    Article  PubMed  PubMed Central  Google Scholar 

  2. Kutoh E, Hirate M, Ikeno Y (2014) Teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes. J Clin Med Res 6(4):287–294. https://doi.org/10.14740/jocmr1841e

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Deacon CF (2020) Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16(11):642–653. https://doi.org/10.1038/s41574-020-0399-8

    Article  CAS  PubMed  Google Scholar 

  4. Yamagishi S, Ishibashi Y, Ojima A, Sugiura T, Matsui T (2014) Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor, decreases serum uric acid levels in type 2 diabetic patients partly by suppressing xanthine oxidase activity. Int J Cardiol 176(2):550–552. https://doi.org/10.1016/j.ijcard.2014.07.023

    Article  PubMed  Google Scholar 

  5. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T (2003) An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 278(3):1848–1855. https://doi.org/10.1074/jbc.M208307200

    Article  CAS  PubMed  Google Scholar 

  6. Matsumoto K, Okamoto K, Ashizawa N, Nishino T (2011) FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther 336(1):95–103. https://doi.org/10.1124/jpet.110.174540

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare, 13-1 Higashi-Kaigan-Cho, Atami, Shizuoka, 413-8790, Japan

    Masayuki Tanemoto, Takahiro Kasai & Yoshito Iida

Authors
  1. Masayuki Tanemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takahiro Kasai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshito Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Tanemoto.

Ethics declarations

Conflict of interest

No conflict of interest was declared.

Consent for publication

Written informed consent was obtained for the publication.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tanemoto, M., Kasai, T. & Iida, Y. Linagliptin possibly enhances the efficacy of allosteric xanthine oxidase inhibitors. Int Urol Nephrol 56, 355–356 (2024). https://doi.org/10.1007/s11255-023-03625-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-023-03625-x

Keywords

Search

Navigation